{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T12:11:55Z","timestamp":1793362315382,"version":"4.5.0"},"reference-count":94,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["General Hospital Psychiatry"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.genhosppsych.2025.12.009","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T16:09:50Z","timestamp":1765901390000},"page":"116-125","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Eligibility for psychedelic therapy: Clinical trial medical exclusion criteria and their implications for hospital practice"],"prefix":"10.1016","volume":"98","author":[{"given":"Martin L.","family":"Williams","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Hitchcock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angus H.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon A.","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.genhosppsych.2025.12.009_bb0005","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1055\/a-1310-3990","article-title":"The history of psychedelics in psychiatry","volume":"54","author":"Nichols","year":"2021","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.genhosppsych.2025.12.009_bb0010","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.neuropharm.2017.12.040","article-title":"Psychiatry & the psychedelic drugs. Past, present & future","volume":"142","author":"Rucker","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.genhosppsych.2025.12.009_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2023.115531","article-title":"Psilocybin-assisted therapy for depression: a systematic review and meta-analysis","volume":"329","author":"Haikazian","year":"2023","journal-title":"Psychiatry Res"},{"issue":"8","key":"10.1016\/j.genhosppsych.2025.12.009_bb0020","doi-asserted-by":"crossref","first-page":"829","DOI":"10.3390\/brainsci14080829","article-title":"Comparison between single-dose and two-dose psilocybin administration in the treatment of major depression: a systematic review and meta-analysis of current clinical trials","volume":"14","author":"Salvetti","year":"2024","journal-title":"Brain Sci"},{"issue":"2","key":"10.1016\/j.genhosppsych.2025.12.009_bb0025","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s13670-023-00383-7","article-title":"Psilocybin in palliative care: an update","volume":"12","author":"Whinkin","year":"2023","journal-title":"Curr Geriatr Rep"},{"key":"10.1016\/j.genhosppsych.2025.12.009_bb0030","article-title":"Psychedelics as an intervention for psychological, existential distress in terminally ill patients: a systematic review and network meta-analysis","volume":"10","author":"Marchi","year":"2024","journal-title":"J Psychopharmacol"},{"issue":"12","key":"10.1016\/j.genhosppsych.2025.12.009_bb0035","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyae057","article-title":"Psychedelics for the treatment of obsessive-compulsive disorder: efficacy and proposed mechanisms","volume":"27","author":"Collins","year":"2024","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.genhosppsych.2025.12.009_bb0040","doi-asserted-by":"crossref","DOI":"10.1111\/add.16762","article-title":"Psychedelic-assisted treatment for substance use disorder: a narrative systematic review","author":"Piper","year":"2025","journal-title":"Addiction"},{"key":"10.1016\/j.genhosppsych.2025.12.009_bb0045","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/7854_2021_284","article-title":"Psychedelic-assisted therapy for substance use disorders and potential mechanisms of action","volume":"56","author":"Rieser","year":"2022","journal-title":"Curr Top Behav Neurosci"},{"key":"10.1016\/j.genhosppsych.2025.12.009_bb0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.euroneuro.2023.05.008","article-title":"Psychedelics in the treatment of eating disorders: rationale and potential mechanisms","volume":"75","author":"Calder","year":"2023","journal-title":"Eur Neuropsychopharmacol"},{"issue":"1","key":"10.1016\/j.genhosppsych.2025.12.009_bb0055","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s40337-024-01125-6","article-title":"Psychedelics and the treatment of eating disorders: considerations for future research and practice","volume":"12","author":"Lacroix","year":"2024","journal-title":"J Eat Disord"},{"issue":"7969","key":"10.1016\/j.genhosppsych.2025.12.009_bb0060","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/d41586-023-02093-8","article-title":"Australia to prescribe MDMA and psilocybin for PTSD and depression in world first","volume":"619","author":"Haridy","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.genhosppsych.2025.12.009_bb0065","series-title":"Psychedelic-assisted psychotherapy: hope and dilemma","volume":"32","author":"The Lancet Regional Health-Europe.","year":"2023"},{"key":"10.1016\/j.genhosppsych.2025.12.009_bb0070","article-title":"Knowledge gaps in psychedelic medicalisation: clinical studies and regulatory aspects","volume":"3","author":"McCulloch","year":"2024","journal-title":"Neurosci Appl"},{"key":"10.1016\/j.genhosppsych.2025.12.009_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajp.2024.104242","article-title":"Exploring the regulatory framework of psychedelics in the US & Europe","volume":"102","author":"Behera","year":"2024","journal-title":"Asian J Psychiatr"},{"issue":"1","key":"10.1016\/j.genhosppsych.2025.12.009_bb0080","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1001\/jamapsychiatry.2022.4101","article-title":"Psychedelic drug legislative reform and legalization in the US","volume":"80","author":"Siegel","year":"2023","journal-title":"JAMA Psychiatry"},{"issue":"226","key":"10.1016\/j.genhosppsych.2025.12.009_bb0085","article-title":"The varieties of psychedelic law","volume":"15","author":"Marks","year":"2023","journal-title":"Neuropharmacology"},{"issue":"12","key":"10.1016\/j.genhosppsych.2025.12.009_bb0090","article-title":"Translating psychedelic therapies from clinical trials to community clinics: building bridges and addressing potential challenges ahead","volume":"4","author":"Williams","year":"2021","journal-title":"Front Psych"},{"issue":"2","key":"10.1016\/j.genhosppsych.2025.12.009_bb0095","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1124\/pr.115.011478","article-title":"Psychedelics","volume":"68","author":"Nichols","year":"2016","journal-title":"Pharmacol Rev"},{"issue":"4","key":"10.1016\/j.genhosppsych.2025.12.009_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmr.2025.100059","article-title":"5-HT2A receptors: pharmacology and functional selectivity","volume":"77","author":"Cummins","year":"2025","journal-title":"Pharmacol Rev"},{"issue":"2","key":"10.1016\/j.genhosppsych.2025.12.009_bb0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0009019","article-title":"Psychedelics and the human receptorome","volume":"5","author":"Ray","year":"2010","journal-title":"PloS One"},{"issue":"12","key":"10.1016\/j.genhosppsych.2025.12.009_bb0110","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial","volume":"30","author":"Griffiths","year":"2016","journal-title":"J Psychopharmacol"},{"issue":"6","key":"10.1016\/j.genhosppsych.2025.12.009_bb0115","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1177\/0269881108093587","article-title":"Human hallucinogen research: guidelines for safety","volume":"22","author":"Johnson","year":"2008","journal-title":"J Psychopharmacol"},{"issue":"12","key":"10.1016\/j.genhosppsych.2025.12.009_bb0120","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1001\/jamapsychiatry.2024.2546","article-title":"Adverse events in studies of classic psychedelics: a systematic review and meta-analysis","volume":"81","author":"Hinkle","year":"2024","journal-title":"JAMA Psychiatry"},{"issue":"3","key":"10.1016\/j.genhosppsych.2025.12.009_bb0125","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1159\/000499917","article-title":"Have treatment studies of depression become even less generalizable? Applying the inclusion and exclusion criteria in placebo-controlled antidepressant efficacy trials published over 20 years to a clinical sample","volume":"88","author":"Zimmerman","year":"2019","journal-title":"Psychother Psychosom"},{"key":"10.1016\/j.genhosppsych.2025.12.009_bb0130","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/s13063-020-4139-0","article-title":"Exclusion rates in randomized controlled trials of treatments for physical conditions: a systematic review","volume":"21","author":"He","year":"2020","journal-title":"Trials"},{"key":"10.1016\/j.genhosppsych.2025.12.009_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2021.106515","article-title":"Eligibility criteria and clinical trials: an FDA perspective","volume":"109","author":"Duggal","year":"2021","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.genhosppsych.2025.12.009_bb0140","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.pharmthera.2018.11.010","article-title":"Classic psychedelics: an integrative review of epidemiology, therapeutics, mystical experience, and brain network function","volume":"197","author":"Johnson","year":"2019","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.genhosppsych.2025.12.009_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2024.115886","article-title":"Efficacy and safety of psychedelics for the treatment of mental disorders: a systematic review and meta-analysis","volume":"335","author":"Yao","year":"2024","journal-title":"Psychiatry Res"},{"issue":"7","key":"10.1016\/j.genhosppsych.2025.12.009_bb0150","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1038\/s41591-025-03685-9","article-title":"An international Delphi consensus for reporting of setting in psychedelic clinical trials","volume":"31","author":"Pronovost-Morgan","year":"2025","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.genhosppsych.2025.12.009_bb0155","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.3390\/biology12111380","article-title":"A comprehensive review of the current status of the cellular neurobiology of psychedelics","volume":"12","author":"Banushi","year":"2023","journal-title":"Biology"},{"issue":"1","key":"10.1016\/j.genhosppsych.2025.12.009_bb0160","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00210-023-02591-6","article-title":"Lysergic acid diethylamide stimulates cardiac human H2 histamine and cardiac human 5-HT4-serotonin receptors","volume":"397","author":"Gergs","year":"2024","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"Pt A","key":"10.1016\/j.genhosppsych.2025.12.009_bb0165","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.phrs.2016.08.022","article-title":"The hallucinogen d-lysergic diethylamide (LSD) decreases dopamine firing activity through 5-HT1A, D2 and TAAR1 receptors","volume":"113","author":"De Gregorio","year":"2016","journal-title":"Pharmacol Res"},{"issue":"7","key":"10.1016\/j.genhosppsych.2025.12.009_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114505","article-title":"The versatile binding landscape of the TAAR1 pocket for LSD and other antipsychotic drug molecules","volume":"43","author":"Jiang","year":"2024","journal-title":"Cell Rep"},{"issue":"5916","key":"10.1016\/j.genhosppsych.2025.12.009_bb0175","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1126\/science.1166127","article-title":"The hallucinogen N,N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator","volume":"323","author":"Fontanilla","year":"2009","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.genhosppsych.2025.12.009_bb0180","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0106533","article-title":"Psychedelic N,N-dimethyltryptamine and 5-methoxy-N,N-dimethyltryptamine modulate innate and adaptive inflammatory responses through the sigma-1 receptor of human monocyte-derived dendritic cells","volume":"9","author":"Szabo","year":"2014","journal-title":"PloS One"},{"issue":"2","key":"10.1016\/j.genhosppsych.2025.12.009_bb0185","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3390\/brainsci15020117","article-title":"Psychedelic-induced neural plasticity: a comprehensive review and a discussion of clinical implications","volume":"15","author":"Weiss","year":"2025","journal-title":"Brain Sci"},{"issue":"45","key":"10.1016\/j.genhosppsych.2025.12.009_bb0190","doi-asserted-by":"crossref","first-page":"8439","DOI":"10.1523\/JNEUROSCI.1121-22.2022","article-title":"Psychedelics and neural plasticity: therapeutic implications","volume":"42","author":"Grieco","year":"2022","journal-title":"J Neurosci"},{"key":"10.1016\/j.genhosppsych.2025.12.009_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2024.111139","article-title":"The immunomodulatory effects of classical psychedelics: a systematic review of preclinical studies","volume":"136","author":"Low","year":"2025","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.genhosppsych.2025.12.009_bb0200","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/cpt.2821","article-title":"Pharmacokinetics and pharmacodynamics of oral psilocybin administration in healthy participants","volume":"113","author":"Holze","year":"2023","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.genhosppsych.2025.12.009_bb0205","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1080\/03602532.2016.1278228","article-title":"Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance","volume":"49","author":"Dinis-Oliveira","year":"2017","journal-title":"Drug Metab Rev"},{"key":"10.1016\/j.genhosppsych.2025.12.009_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.nsa.2024.104060","article-title":"Safety pharmacology of acute psilocybin administration in healthy participants","volume":"3","author":"Straumann","year":"2024","journal-title":"Neurosci Appl"},{"issue":"3","key":"10.1016\/j.genhosppsych.2025.12.009_bb0215","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1080\/03602532.2019.1638931","article-title":"Metabolism of lysergic acid diethylamide (LSD): an update","volume":"51","author":"Lib\u00e2nio Os\u00f3rio Marta","year":"2019","journal-title":"Drug Metab Rev"},{"issue":"3","key":"10.1016\/j.genhosppsych.2025.12.009_bb0220","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s13318-023-00822-y","article-title":"Pharmacokinetics of N,N-dimethyltryptamine in Humans","volume":"48","author":"Good","year":"2023","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"5","key":"10.1016\/j.genhosppsych.2025.12.009_bb0225","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/dta.1685","article-title":"Metabolism and urinary disposition of N,N-dimethyltryptamine after oral and smoked administration: a comparative study","volume":"7","author":"Riba","year":"2015","journal-title":"Drug Test Anal"},{"issue":"8","key":"10.1016\/j.genhosppsych.2025.12.009_bb0230","doi-asserted-by":"crossref","first-page":"659","DOI":"10.2174\/138920010794233495","article-title":"Psychedelic 5-methoxy-N,N-dimethyltryptamine: metabolism, pharmacokinetics, drug interactions, and pharmacological actions","volume":"11","author":"Shen","year":"2010","journal-title":"Curr Drug Metab"},{"issue":"1","key":"10.1016\/j.genhosppsych.2025.12.009_bb0235","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.bcp.2010.02.020","article-title":"Effects of monoamine oxidase inhibitor and cytochrome P450 2D6 status on 5-methoxy-N,N-dimethyltryptamine metabolism and pharmacokinetics","volume":"80","author":"Shen","year":"2010","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"10.1016\/j.genhosppsych.2025.12.009_bb0240","doi-asserted-by":"crossref","first-page":"184","DOI":"10.2174\/1874467211666181010154139","article-title":"Pharmacokinetic and pharmacodynamic aspects of peyote and mescaline: clinical and forensic repercussions","volume":"12","author":"Dinis-Oliveira","year":"2019","journal-title":"Curr Mol Pharmacol"},{"key":"10.1016\/j.genhosppsych.2025.12.009_bb0245","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"16","key":"10.1016\/j.genhosppsych.2025.12.009_bb0250","article-title":"Editorial: beyond psilocybin: exploring the clinical potential of alternative and novel psychedelics","volume":"23","author":"Williams","year":"2025","journal-title":"Front Psych"},{"key":"10.1016\/j.genhosppsych.2025.12.009_bb0255","author":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use"},{"issue":"12","key":"10.1016\/j.genhosppsych.2025.12.009_bb0260","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s00228-008-0553-z","article-title":"Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction","volume":"64","author":"Verbeeck","year":"2008","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.genhosppsych.2025.12.009_bb0265","doi-asserted-by":"crossref","first-page":"32","DOI":"10.18773\/austprescr.2009.018","article-title":"Prescribing in liver disease","volume":"32","author":"Sloss","year":"2009","journal-title":"Aust Prescr"},{"issue":"3","key":"10.1016\/j.genhosppsych.2025.12.009_bb0270","doi-asserted-by":"crossref","first-page":"96","DOI":"10.18773\/austprescr.2021.015","article-title":"Managing medicines in alcohol-associated liver disease: a practical review","volume":"44","author":"Johnson","year":"2021","journal-title":"Aust Prescr"},{"issue":"4","key":"10.1016\/j.genhosppsych.2025.12.009_bb0275","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/bcp.12086","article-title":"Renal drug metabolism in humans: the potential for drug-endobiotic interactions involving cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT)","volume":"76","author":"Knights","year":"2013","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.genhosppsych.2025.12.009_bb0280","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40262-012-0018-5","article-title":"The clinical relevance of plasma protein binding changes","volume":"52","author":"Roberts","year":"2013","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.genhosppsych.2025.12.009_bb0285","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.bcp.2019.04.013","article-title":"Cytochrome P450 enzymes contribute to the metabolism of LSD to nor-LSD and 2-oxo-3-hydroxy-LSD: implications for clinical LSD use","volume":"164","author":"Luethi","year":"2019","journal-title":"Biochem Pharmacol"},{"issue":"6","key":"10.1016\/j.genhosppsych.2025.12.009_bb0290","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1002\/cpt.1434","article-title":"Pharmacodynamic drug-drug interactions","volume":"105","author":"Niu","year":"2019","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.genhosppsych.2025.12.009_bb0295","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1208\/s12248-013-9530-2","article-title":"Impact of genetic polymorphism on drug-drug interactions mediated by cytochromes: a general approach","volume":"15","author":"Tod","year":"2013","journal-title":"AAPS J"},{"issue":"23","key":"10.1016\/j.genhosppsych.2025.12.009_bb0300","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222312808","article-title":"Cytochrome P450 enzymes and drug metabolism in humans","volume":"22","author":"Zhao","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.genhosppsych.2025.12.009_bb0305","doi-asserted-by":"crossref","first-page":"554","DOI":"10.3390\/jpm11060554","article-title":"The functionality of UDP-glucuronosyltransferase genetic variants and their association with drug responses and human diseases","volume":"11","author":"Jarrar","year":"2021","journal-title":"J Pers Med"},{"issue":"1","key":"10.1016\/j.genhosppsych.2025.12.009_bb0310","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/02698811231211219","article-title":"Drug-drug interactions involving classic psychedelics: a systematic review","volume":"38","author":"Halman","year":"2024","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.genhosppsych.2025.12.009_bb0315","series-title":"Curr. Top. Behav. Neurosci","doi-asserted-by":"crossref","DOI":"10.1007\/7854_2024_508","article-title":"Toxicology and pharmacological interactions of classic psychedelics","author":"Thomas","year":"2024"},{"key":"10.1016\/j.genhosppsych.2025.12.009_bb0320","series-title":"Curr. Top. Behav. Neurosci","doi-asserted-by":"crossref","DOI":"10.1007\/7854_2024_510","article-title":"Pharmacological properties of psychedelics with a special focus on potential harms","author":"Holze","year":"2024"},{"issue":"1","key":"10.1016\/j.genhosppsych.2025.12.009_bb0325","doi-asserted-by":"crossref","first-page":"10851","DOI":"10.1038\/s41598-021-90343-y","article-title":"Genetic influence of CYP2D6 on pharmacokinetics and acute subjective effects of LSD in a pooled analysis","volume":"11","author":"Vizeli","year":"2021","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.genhosppsych.2025.12.009_bb0330","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1007\/s00213-021-05876-x","article-title":"Serotonin toxicity of serotonergic psychedelics","volume":"239","author":"Malcolm","year":"2022","journal-title":"Psychopharmacology (Berl)"},{"issue":"Sup 1","key":"10.1016\/j.genhosppsych.2025.12.009_bb0335","article-title":"Assessment of the CYP450 inhibitory potential of LSD, 5-MeO-DMT and mescaline: an in vitro study","volume":"1","author":"Silva-Carvalho","year":"2023","journal-title":"Sci Lett"},{"issue":"1","key":"10.1016\/j.genhosppsych.2025.12.009_bb0345","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1080\/02791072.2020.1815911","article-title":"Chemical composition of traditional and analog ayahuasca","volume":"53","author":"Kaasik","year":"2021","journal-title":"J Psychoactive Drugs"},{"issue":"4","key":"10.1016\/j.genhosppsych.2025.12.009_bb0350","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1755-5949.2008.00059.x","article-title":"The pharmacology of lysergic acid diethylamide: a review","volume":"14","author":"Passie","year":"2008","journal-title":"CNS Neurosci Ther"},{"issue":"1","key":"10.1016\/j.genhosppsych.2025.12.009_bb0355","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s40262-024-01454-4","article-title":"Clinical pharmacokinetics of psilocin after psilocybin administration: a systematic review and post-hoc analysis","volume":"64","author":"Otto","year":"2025","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"10.1016\/j.genhosppsych.2025.12.009_bb0360","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1124\/dmd.121.000530","article-title":"Inhibition of UDP-glucuronosyltransferase enzymes by major cannabinoids and their metabolites","volume":"49","author":"Nasrin","year":"2021","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"10.1016\/j.genhosppsych.2025.12.009_bb0365","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1124\/dmd.114.062141","article-title":"Targeted screen for human UDP-glucuronosyltransferases inhibitors and the evaluation of potential drug-drug interactions with zafirlukast","volume":"43","author":"Oda","year":"2015","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.genhosppsych.2025.12.009_bb0370","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1177\/02698811231224217","article-title":"Interactions between classic psychedelics and serotonergic antidepressants: effects on the acute psychedelic subjective experience, well-being and depressive symptoms from a prospective survey study","volume":"38","author":"Barbut Siva","year":"2024","journal-title":"J Psychopharmacol"},{"issue":"4","key":"10.1016\/j.genhosppsych.2025.12.009_bb0375","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/cpt.2487","article-title":"Acute effects of psilocybin after escitalopram or placebo pretreatment in a randomized, double-blind, placebo-controlled, crossover study in healthy subjects","volume":"111","author":"Becker","year":"2022","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.genhosppsych.2025.12.009_bb0380","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1002\/cpt.3618","article-title":"Acute effects and pharmacokinetics of LSD after paroxetine or placebo pre-administration in a randomized, double-blind, cross-over phase I trial","volume":"117","author":"Becker","year":"2025","journal-title":"Clin Pharmacol Ther"},{"issue":"6633","key":"10.1016\/j.genhosppsych.2025.12.009_bb0385","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1126\/science.adf0435","article-title":"Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors","volume":"379","author":"Vargas","year":"2023","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.genhosppsych.2025.12.009_bb0390","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1177\/02698811231179910","article-title":"Attenuation of psilocybin mushroom effects during and after SSRI\/SNRI antidepressant use","volume":"37","author":"Gukasyan","year":"2023","journal-title":"J Psychopharmacol"},{"issue":"10","key":"10.1016\/j.genhosppsych.2025.12.009_bb0395","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1038\/s41386-023-01648-7","article-title":"Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication","volume":"48","author":"Goodwin","year":"2023","journal-title":"Neuropsychopharmacol"},{"issue":"5","key":"10.1016\/j.genhosppsych.2025.12.009_bb0400","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1055\/a-1524-2794","article-title":"Classic psychedelic coadministration with Lithium, but not lamotrigine, is associated with seizures: an analysis of online psychedelic experience reports","volume":"54","author":"Nayak","year":"2021","journal-title":"Pharmacopsychiatry"},{"issue":"6","key":"10.1016\/j.genhosppsych.2025.12.009_bb0405","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1007\/s43440-023-00539-4","article-title":"Cardiovascular safety of psychedelic medicine: current status and future directions","volume":"75","author":"Ws\u00f3\u0142","year":"2023","journal-title":"Pharmacol Rep"},{"issue":"3","key":"10.1016\/j.genhosppsych.2025.12.009_bb0410","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1161\/hy0302.105777","article-title":"Blood pressure response to heart rate during exercise test and risk of future hypertension","volume":"39","author":"Miyai","year":"2002","journal-title":"Hypertension"},{"issue":"5","key":"10.1016\/j.genhosppsych.2025.12.009_bb0415","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.hlc.2018.04.279","article-title":"Estimation of the blood pressure response with exercise stress testing","volume":"28","author":"Fitzgerald","year":"2019","journal-title":"Heart Lung Circ"},{"issue":"2","key":"10.1016\/j.genhosppsych.2025.12.009_bb0420","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s44161-025-00608-2","article-title":"Cardiovascular effects and safety of classic psychedelics","volume":"4","author":"Nahlawi","year":"2025","journal-title":"Nat Cardiovasc Res"},{"issue":"8","key":"10.1016\/j.genhosppsych.2025.12.009_bb0425","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1021\/acsptsci.3c00123","article-title":"Transient elevation of plasma glucocorticoids supports psilocybin-induced anxiolysis in mice","volume":"6","author":"Jones","year":"2023","journal-title":"ACS Pharmacol Transl Sci"},{"key":"10.1016\/j.genhosppsych.2025.12.009_bb0430","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3389\/fphar.2018.00177","article-title":"Neuroendocrine associations underlying the persistent therapeutic effects of classic serotonergic psychedelics","volume":"9","author":"Schindler","year":"2018","journal-title":"Front Pharmacol"},{"issue":"2","key":"10.1016\/j.genhosppsych.2025.12.009_bb0435","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s00213-003-1640-6","article-title":"Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study","volume":"172","author":"Hasler","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"issue":"11","key":"10.1016\/j.genhosppsych.2025.12.009_bb0440","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.45278","article-title":"Oxytocin and the role of fluid restriction in MDMA-induced hyponatremia: a secondary analysis of 4 randomized clinical trials","volume":"7","author":"Atila","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.genhosppsych.2025.12.009_bb0445","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpnec.2025.100303","article-title":"The psychedelic-peptide paradox: a hormetic hypothesis","volume":"23","author":"Carter","year":"2025","journal-title":"Compr Psychoneuroendocrinol"},{"issue":"10","key":"10.1016\/j.genhosppsych.2025.12.009_bb0450","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.tips.2023.08.001","article-title":"A perspective on psychedelic teratogenicity: the utility of zebrafish models","volume":"44","author":"Syed","year":"2023","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.genhosppsych.2025.12.009_bb0455","doi-asserted-by":"crossref","first-page":"8630","DOI":"10.1038\/s41467-025-64371-5","article-title":"Psilocybin during the postpartum period induces long-lasting adverse effects in both mothers and offspring","volume":"16","author":"Hatzipantelis","year":"2025","journal-title":"Nat Commun"},{"issue":"8","key":"10.1016\/j.genhosppsych.2025.12.009_bb0460","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1177\/02698811221093793","article-title":"Postpartum depression: a role for psychedelics?","volume":"36","author":"Jairaj","year":"2022","journal-title":"J Psychopharmacol"},{"issue":"8","key":"10.1016\/j.genhosppsych.2025.12.009_bb0465","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1002\/psp4.12662","article-title":"Prediction of drug concentrations in milk during breastfeeding, integrating predictive algorithms within a physiologically-based pharmacokinetic model","volume":"10","author":"Abduljalil","year":"2021","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"9","key":"10.1016\/j.genhosppsych.2025.12.009_bb0470","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1111\/add.16518","article-title":"A retrospective study of the characteristics and toxicology of cases of lysergic acid diethylamide (LSD)- and psilocybin-related death in Australia","volume":"119","author":"Darke","year":"2024","journal-title":"Addiction"},{"issue":"4","key":"10.1016\/j.genhosppsych.2025.12.009_bb0475","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1080\/02791072.2022.2108356","article-title":"Naturalistic psychedelic use: a world apart from clinical care","volume":"55","author":"Glynos","year":"2023","journal-title":"J Psychoactive Drugs"}],"container-title":["General Hospital Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163834325002385?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163834325002385?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T14:34:42Z","timestamp":1769178882000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163834325002385"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":94,"alternative-id":["S0163834325002385"],"URL":"https:\/\/doi.org\/10.1016\/j.genhosppsych.2025.12.009","relation":{},"ISSN":["0163-8343"],"issn-type":[{"value":"0163-8343","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Eligibility for psychedelic therapy: Clinical trial medical exclusion criteria and their implications for hospital practice","name":"articletitle","label":"Article Title"},{"value":"General Hospital Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.genhosppsych.2025.12.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}